“减肥双雄”首次“头对头”PK：礼来赢了诺和诺德，高盛：市场早就知道了

华尔街见闻12-05

礼来公司后来居上，与诺和诺德展开激烈的市场份额争夺。减肥药届“双雄”的“拉锯战”加剧！礼来公司近期公布的一项研究结果显示，其减肥药Zepbound 在与诺和诺德的Wegovy的首次“头对头”临床试验中表现更加优异。在该项临床测试中，使用Zepbound的参与者在72周内平均减轻了20.2%的体重，而使用诺和诺德的Wegovy的参与者减轻了13.7%。这意味着服用Zepbound的人平均减掉了...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2489248313?lang=zh_CN&edition=full","thumbnail":"https://wpimg-wscn.awtmt.com/7678664b-3b5f-4fc3-ab6c-6b8931f66efb.jpeg","is_english":false,"pubTime":"2024-12-05 15:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2489248313","market":"hk","top_or_hot":-1,"title":"“减肥双雄”首次“头对头”PK：礼来赢了诺和诺德，高盛：市场早就知道了","media":"华尔街见闻","content":"<div>\n<p>礼来公司后来居上，与诺和诺德展开激烈的市场份额争夺。减肥药届“双雄”的“拉锯战”加剧！\n礼来公司近期公布的一项研究结果显示，其减肥药Zepbound 在与诺和诺德的Wegovy的首次“头对头”临床试验中表现更加优异。\n在该项临床测试中，使用Zepbound的参与者在72周内平均减轻了20.2%的体重，而使用诺和诺德的Wegovy的参与者减轻了13.7%。这意味着服用Zepbound的人平均减掉了...</p>\n\n<a href=\"https://wallstreetcn.com/articles/3736139\">网页链接</a>\n\n</div>\n","source":"wallstreetcn_hot_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>“减肥双雄”首次“头对头”PK：礼来赢了诺和诺德，高盛：市场早就知道了</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n“减肥双雄”首次“头对头”PK：礼来赢了诺和诺德，高盛：市场早就知道了\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-05 15:03 北京时间&nbsp;&nbsp;&nbsp;<a href=https://wallstreetcn.com/articles/3736139><strong>华尔街见闻</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>礼来公司后来居上，与诺和诺德展开激烈的市场份额争夺。减肥药届“双雄”的“拉锯战”加剧！\n礼来公司近期公布的一项研究结果显示，其减肥药Zepbound 在与诺和诺德的Wegovy的首次“头对头”临床试验中表现更加优异。\n在该项临床测试中，使用Zepbound的参与者在72周内平均减轻了20.2%的体重，而使用诺和诺德的Wegovy的参与者减轻了13.7%。这意味着服用Zepbound的人平均减掉了...</p>\n\n<a href=\"https://wallstreetcn.com/articles/3736139\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2237443978.SGD","symbol_name":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","start_time":0,"source_url":"https://wallstreetcn.com/articles/3736139","article_id":"2489248313","we_media_id":null,"thumbnails":["https://wpimg-wscn.awtmt.com/7678664b-3b5f-4fc3-ab6c-6b8931f66efb.jpeg"],"rights":{"source":"wallstreetcn_hot_news","url":"https://wallstreetcn.com/articles/3736139","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2489248313","pubTimestamp":1733382221,"columns":[],"sourceInfo":{"source_id":"wallstreetcn_hot_news","name":"华尔街见闻"},"weMediaInfo":null,"summary":"高盛表示，这一结果符合市场普遍预期，即Zepbound的减肥效果显著优于诺和诺德。并认为诺和诺德与礼来将控制80%的减肥药市场，二者间的比例为40%和60%。","collect":0,"end_time":0,"defaultTopTitle":"wallstreetcn.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU0203202063.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A2X\" (USD) ACC","IE00BK4W5L77.USD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (USD) ACC","IE00BK4W5M84.HKD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (HKD) ACC","SG9999015978.USD":"利安颠覆性创新基金A","LLY":"礼来","SG9999014898.SGD":"United Global Quality Growth Fund Dis SGD","BK4504":"桥水持仓","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","NVO":"诺和诺德","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","PK":"Park Hotels & Resorts Inc.","BK4127":"投资银行业与经纪业","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","BK4516":"特朗普概念","BK4532":"文艺复兴科技持仓","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","SG9999018865.SGD":"United Global Quality Growth Fd Cl Dist SGD-H","SG9999014914.USD":"UNITED GLOBAL QUALITY GROWTH (USDHDG) INC","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU2360106947.USD":"BGF NUTRITION \"A4\" (USD) INC","LU0109391861.USD":"富兰克林美国机遇基金A Acc","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU0238689110.USD":"贝莱德环球动力股票基金","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU1127390331.HKD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A\" (HKD) ACC","SGXZ51526630.SGD":"大华环球创新基金A Acc SGD","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1868837300.USD":"CT (LUX) I AMERICAN FUND \"9\" (USD) ACC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC"},"translate_title":"\"Weight loss duo\" first \"head-to-head\" PK: Eli Lilly won Novo Nordisk, Goldman Sachs: The market has long known it","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PK":1,"NVO":1,"LLY":1},"content_text":"礼来公司后来居上，与诺和诺德展开激烈的市场份额争夺。减肥药届“双雄”的“拉锯战”加剧！\n礼来公司近期公布的一项研究结果显示，其减肥药Zepbound 在与诺和诺德的Wegovy的首次“头对头”临床试验中表现更加优异。\n在该项临床测试中，使用Zepbound的参与者在72周内平均减轻了20.2%的体重，而使用诺和诺德的Wegovy的参与者减轻了13.7%。这意味着服用Zepbound的人平均减掉了50磅，而服用Wegovy者减掉了33磅。\n对此，高盛在4日发布的研报中表示，这一结果符合市场普遍预期，即Zepbound的减肥效果显著优于竞争对手。并认为诺和诺德与礼来将控制80%的减肥药市场，二者间的比例为40%和60%。\n高盛：Zepbound效果胜出，结果符合预期\n在这项研究包括来自美国和波多黎各的751名参与者，他们接受了能够耐受的最高剂量药物治疗。\n研究结果显示，接受Zepbound治疗的参与者在72周内平均减轻了20.2%的体重，约50磅，而接受Wegovy治疗的参与者平均仅减轻了13.7%。\n这意味着服用Zepbound的人平均减掉了50磅，而Wegovy用户减掉了33磅。\n高盛在研报中表示，这一结果符合市场普遍预期，参考先前注册研究数据显示，礼来的的SURMOUNT-1试验在72周的减重效果为20.9%，而诺和诺德的数据显示为14.9%。\n\n“我们认为，媒体对这项研究的关注主要反映了公众对减肥治疗的持续兴趣，而非带来颠覆性的市场变化。我们的模型预测，诺和诺德与礼来将控制80%的减肥药市场，二者间的比例为40%和60%。”\n\n市场对肥胖治疗的关注仍然强烈。报告指出，未来的基本讨论仍集中在需求强度、生产规模扩展、供应链动态以及下一代药物的数据更新，特别是诺和诺德的CagriSema数据。\n后来居上，压力给到诺和诺德！\n诺和诺德方面回应称，Wegovy是唯一被证明可以降低心脏病和肥胖症患者心脏病发作和中风风险的抗肥胖药物。\n瑞穗分析师Jared Holz将礼来和诺和诺德之间的竞争称为“永恒的跳跃游戏”。他表示，Zepbound的减重效果符合此前试验中报告的数据，而Wegovy的减重效果则位于该药物长期试验范围的低端。这一结果更有利于礼来在激烈的竞争中抢占更多市场份额。\n目前，减肥药市场正成为制药行业增长最快的领域之一。行业预测到2030年，该市场规模将达到1300亿美元。\n诺和诺德凭借GLP-1类药物的先发优势，目前在该领域占据领先地位。然而，这一新试验结果可能对其市场地位构成威胁。风险提示及免责条款\n\n            市场有风险，投资需谨慎。本文不构成个人投资建议，也未考虑到个别用户特殊的投资目标、财务状况或需要。用户应考虑本文中的任何意见、观点或结论是否符合其特定状况。据此投资，责任自负。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2489248313"}